Identification of small compound biomarkers of pituitary adenoma: A bilateral inferior petrosal sinus sampling study

Rahmi Oklu, Amy R. Deipolyi, Stephan Wicky, Emel Ergul, Amy A. Deik, John W. Chen, Joshua A. Hirsch, Gregory R. Wojtkiewicz, Clary B. Clish

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Evaluation of the pathogenic mechanisms underlying Cushing disease (CD) is limited partly by the inaccessibility of the pituitary gland for biopsy. We used bilateral inferior petrosal sinus sampling (BIPSS), the gold standard in diagnosing pituitary sources of CD, to obtain central blood samples for in vivo metabolomic analysis of pathways involved in pituitary adenomas. We evaluated 16 samples from eight patients who underwent BIPSS to measure adrenocorticotropic hormone (ACTH) levels in the inferior petrosal sinus (IPS) bilaterally. Seven patients had CD with concordant BIPSS, surgical, and pathologic findings. Samples from the IPS contralateral to histologically proven lesions were used as controls. BIPSS of the eighth patient revealed no central pituitary ACTH source, and these samples were also included as controls. Plasma samples were profiled using a combination of three liquid chromatography tandem mass spectrometry methods, which assessed 259 metabolites. Following Bonferroni correction for multiple comparisons, three small compound biomarkers of CD (pyridoxate, deoxycholic acid, and 3-methyladipate) were identified to be signi ficantly altered in pituitary adenomas. The pathway most significantly impacted in CD samples is one previously shown to be upregulated in other cancers. Exploiting the BIPSS technique, we showed a complete metabolite and lipid profile of pituitary adenomas in CD. These potential biomarkers of CD may elucidate tumor biology and suggest possible diagnostic molecular imaging probes as well as therapeutic targets in patients with recurrent disease after surgery.

Original languageEnglish (US)
Pages (from-to)541-546
Number of pages6
JournalJournal of NeuroInterventional Surgery
Volume6
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Petrosal Sinus Sampling
Pituitary ACTH Hypersecretion
Sampling Studies
Pituitary Neoplasms
Biomarkers
Adrenocorticotropic Hormone
Molecular Probes
Molecular Imaging
Deoxycholic Acid
Metabolomics
Pituitary Hormones
Pituitary Gland
Diagnostic Imaging
Tandem Mass Spectrometry
Liquid Chromatography
Neoplasms
Lipids
Biopsy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Medicine(all)

Cite this

Identification of small compound biomarkers of pituitary adenoma : A bilateral inferior petrosal sinus sampling study. / Oklu, Rahmi; Deipolyi, Amy R.; Wicky, Stephan; Ergul, Emel; Deik, Amy A.; Chen, John W.; Hirsch, Joshua A.; Wojtkiewicz, Gregory R.; Clish, Clary B.

In: Journal of NeuroInterventional Surgery, Vol. 6, No. 7, 2014, p. 541-546.

Research output: Contribution to journalArticle

Oklu, Rahmi ; Deipolyi, Amy R. ; Wicky, Stephan ; Ergul, Emel ; Deik, Amy A. ; Chen, John W. ; Hirsch, Joshua A. ; Wojtkiewicz, Gregory R. ; Clish, Clary B. / Identification of small compound biomarkers of pituitary adenoma : A bilateral inferior petrosal sinus sampling study. In: Journal of NeuroInterventional Surgery. 2014 ; Vol. 6, No. 7. pp. 541-546.
@article{22b3b85a8a944e7d851c6760c080e7e3,
title = "Identification of small compound biomarkers of pituitary adenoma: A bilateral inferior petrosal sinus sampling study",
abstract = "Evaluation of the pathogenic mechanisms underlying Cushing disease (CD) is limited partly by the inaccessibility of the pituitary gland for biopsy. We used bilateral inferior petrosal sinus sampling (BIPSS), the gold standard in diagnosing pituitary sources of CD, to obtain central blood samples for in vivo metabolomic analysis of pathways involved in pituitary adenomas. We evaluated 16 samples from eight patients who underwent BIPSS to measure adrenocorticotropic hormone (ACTH) levels in the inferior petrosal sinus (IPS) bilaterally. Seven patients had CD with concordant BIPSS, surgical, and pathologic findings. Samples from the IPS contralateral to histologically proven lesions were used as controls. BIPSS of the eighth patient revealed no central pituitary ACTH source, and these samples were also included as controls. Plasma samples were profiled using a combination of three liquid chromatography tandem mass spectrometry methods, which assessed 259 metabolites. Following Bonferroni correction for multiple comparisons, three small compound biomarkers of CD (pyridoxate, deoxycholic acid, and 3-methyladipate) were identified to be signi ficantly altered in pituitary adenomas. The pathway most significantly impacted in CD samples is one previously shown to be upregulated in other cancers. Exploiting the BIPSS technique, we showed a complete metabolite and lipid profile of pituitary adenomas in CD. These potential biomarkers of CD may elucidate tumor biology and suggest possible diagnostic molecular imaging probes as well as therapeutic targets in patients with recurrent disease after surgery.",
author = "Rahmi Oklu and Deipolyi, {Amy R.} and Stephan Wicky and Emel Ergul and Deik, {Amy A.} and Chen, {John W.} and Hirsch, {Joshua A.} and Wojtkiewicz, {Gregory R.} and Clish, {Clary B.}",
year = "2014",
doi = "10.1136/neurintsurg-2013-010821",
language = "English (US)",
volume = "6",
pages = "541--546",
journal = "Journal of NeuroInterventional Surgery",
issn = "1759-8478",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - Identification of small compound biomarkers of pituitary adenoma

T2 - A bilateral inferior petrosal sinus sampling study

AU - Oklu, Rahmi

AU - Deipolyi, Amy R.

AU - Wicky, Stephan

AU - Ergul, Emel

AU - Deik, Amy A.

AU - Chen, John W.

AU - Hirsch, Joshua A.

AU - Wojtkiewicz, Gregory R.

AU - Clish, Clary B.

PY - 2014

Y1 - 2014

N2 - Evaluation of the pathogenic mechanisms underlying Cushing disease (CD) is limited partly by the inaccessibility of the pituitary gland for biopsy. We used bilateral inferior petrosal sinus sampling (BIPSS), the gold standard in diagnosing pituitary sources of CD, to obtain central blood samples for in vivo metabolomic analysis of pathways involved in pituitary adenomas. We evaluated 16 samples from eight patients who underwent BIPSS to measure adrenocorticotropic hormone (ACTH) levels in the inferior petrosal sinus (IPS) bilaterally. Seven patients had CD with concordant BIPSS, surgical, and pathologic findings. Samples from the IPS contralateral to histologically proven lesions were used as controls. BIPSS of the eighth patient revealed no central pituitary ACTH source, and these samples were also included as controls. Plasma samples were profiled using a combination of three liquid chromatography tandem mass spectrometry methods, which assessed 259 metabolites. Following Bonferroni correction for multiple comparisons, three small compound biomarkers of CD (pyridoxate, deoxycholic acid, and 3-methyladipate) were identified to be signi ficantly altered in pituitary adenomas. The pathway most significantly impacted in CD samples is one previously shown to be upregulated in other cancers. Exploiting the BIPSS technique, we showed a complete metabolite and lipid profile of pituitary adenomas in CD. These potential biomarkers of CD may elucidate tumor biology and suggest possible diagnostic molecular imaging probes as well as therapeutic targets in patients with recurrent disease after surgery.

AB - Evaluation of the pathogenic mechanisms underlying Cushing disease (CD) is limited partly by the inaccessibility of the pituitary gland for biopsy. We used bilateral inferior petrosal sinus sampling (BIPSS), the gold standard in diagnosing pituitary sources of CD, to obtain central blood samples for in vivo metabolomic analysis of pathways involved in pituitary adenomas. We evaluated 16 samples from eight patients who underwent BIPSS to measure adrenocorticotropic hormone (ACTH) levels in the inferior petrosal sinus (IPS) bilaterally. Seven patients had CD with concordant BIPSS, surgical, and pathologic findings. Samples from the IPS contralateral to histologically proven lesions were used as controls. BIPSS of the eighth patient revealed no central pituitary ACTH source, and these samples were also included as controls. Plasma samples were profiled using a combination of three liquid chromatography tandem mass spectrometry methods, which assessed 259 metabolites. Following Bonferroni correction for multiple comparisons, three small compound biomarkers of CD (pyridoxate, deoxycholic acid, and 3-methyladipate) were identified to be signi ficantly altered in pituitary adenomas. The pathway most significantly impacted in CD samples is one previously shown to be upregulated in other cancers. Exploiting the BIPSS technique, we showed a complete metabolite and lipid profile of pituitary adenomas in CD. These potential biomarkers of CD may elucidate tumor biology and suggest possible diagnostic molecular imaging probes as well as therapeutic targets in patients with recurrent disease after surgery.

UR - http://www.scopus.com/inward/record.url?scp=84905909923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905909923&partnerID=8YFLogxK

U2 - 10.1136/neurintsurg-2013-010821

DO - 10.1136/neurintsurg-2013-010821

M3 - Article

C2 - 24005126

AN - SCOPUS:84905909923

VL - 6

SP - 541

EP - 546

JO - Journal of NeuroInterventional Surgery

JF - Journal of NeuroInterventional Surgery

SN - 1759-8478

IS - 7

ER -